| SEGMENT INFORMATION |
NOTE 16 – SEGMENT INFORMATION The Company determines its reportable segments based on its internal organization structure and internal management reporting used to assess and allocate resources. This information is regularly reviewed by the Company’s Chief Executive Officer who is identified as the Chief Operating Decision Maker (“CODM”). The Company consists of three operating units, BioNexus Gene Lab Corp., MRNA Scientific Sdn. Bhd. and Chemrex Corporation Sdn. Bhd. which are determined as three reportable segments, as described below. These reportable segments offer different products and services, and are managed separately because they require different technology and marketing strategies. The following describes the operations in each of the Company’s reportable segments: · | Trading of industrial chemicals | - | Includes trading of industrial chemicals | · | Provision for genomic screening services | - | includes in commercializing proprietary blood-based diagnostic test for early disease detection | · | Investment holding | - | Investment holding |
The CODM evaluates the performance of each reportable segment based on operating income and key segment-specific metrics. There are no inter-segment revenue transactions between reportable segments. Except for investment holding activities and the revenue to the overseas customers as disclosed in Note 12, the Company’s revenue and principal operations are substantially confined within Malaysia. The CODM evaluates segment performance primarily on operating income and reviews the following expense categories by segment: cost of revenue, selling and distribution, and administrative expenses. A reconciliation of total reportable segment amounts to the Company’s consolidated amounts is provided below, with corporate and unallocated items presented as reconciling adjustments. Pursuant to ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures”, the financial information concerning the Company’s reportable segments is shown as below: Nine-month periods: By Business Unit | | Provision for genomic screening services | | | Trading of industrial chemicals | | | Investment holding | | | Total | | | | Nine-month periods ended September 30, 2026 | | | | | | | | | | | | | | | REVENUE | | $ | 1,961 | | | $ | 144,954 | | | $ | - | | | $ | 146,915 | | | | | | | | | | | | | | | | | | | COST OF REVENUE | | | (1,250 | ) | | | (128,985 | ) | | | - | | | | (130,235 | ) | | | | | | | | | | | | | | | | | | GROSS PROFIT | | | 711 | | | | 15,969 | | | | - | | | | 16,680 | | | | | | | | | | | | | | | | | | | OTHER INCOME | | | | | | | | | | | | | | | | | Interest income | | | 38,273 | | | | 16,630 | | | | - | | | | 54,903 | | Gain from foreign exchange | | | 8,227 | | | | 1,790 | | | | 48 | | | | 10,065 | | Others | | | - | | | | 22,779 | | | | - | | | | 22,779 | | TOTAL OTHER INCOME | | | 46,500 | | | | 41,199 | | | | 48 | | | | 87,747 | | | | | | | | | | | | | | | | | | | OPERATING EXPENSES | | | | | | | | | | | | | | | | | Sales and marketing | | | (98,154 | ) | | | (2,790 | ) | | | (22,818 | ) | | | (123,762 | ) | Research and development | | | (41,736 | ) | | | - | | | | - | | | | (41,736 | ) | General and administrative | | | (180,877 | ) | | | (162,031 | ) | | | (600,034 | ) | | | (942,942 | ) | Provision for credit losses, net | | | - | | | | (76,814 | ) | | | - | | | | (76,814 | ) | Share-based compensation | | | - | | | | - | | | | (799,998 | ) | | | (799,998 | ) | TOTAL OPERATING EXPENSES | | | (320,767 | ) | | | (241,635 | ) | | | (1,422,850 | ) | | | (1,985,252 | ) | | | | | | | | | | | | | | | | | | LOSS FROM OPERATIONS | | | (273,556 | ) | | | (184,467 | ) | | | (1,422,802 | ) | | | (1,880,825 | ) | | | | | | | | | | | | | | | | | | FINANCE COSTS | | | - | | | | (1,574 | ) | | | (2,007 | ) | | | (3,581 | ) | | | | | | | | | | | | | | | | | | LOSS BEFORE TAX | | | (273,556 | ) | | | (186,041 | ) | | | (1,424,809 | ) | | | (1,884,406 | ) | | | | | | | | | | | | | | | | | | Tax expense | | | - | | | | - | | | | - | | | | - | | | | | | | | | | | | | | | | | | | NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | | $ | (273,556 | ) | | $ | (186,041 | ) | | $ | (1,424,809 | ) | | $ | (1,884,406 | ) |
| | Provision for | | | | | | | | | | | | | genomic | | | Trading of | | | | | | | | | | screening | | | industrial | | | Investment | | | | | | | services | | | chemicals | | | holding | | | Total | | | | Nine months period ended September 30, 2025 | | | | | | | | | | | | | | | REVENUE | | $ | 11,302 | | | $ | 6,929,849 | | | $ | - | | | $ | 6,941,151 | | | | | | | | | | | | | | | | | | | COST OF REVENUE | | | (4,995 | ) | | | (5,846,956 | ) | | | - | | | | (5,851,951 | ) | | | | | | | | | | | | | | | | | | GROSS PROFIT | | | 6,307 | | | | 1,082,893 | | | | - | | | | 1,089,200 | | | | | | | | | | | | | | | | | | | OTHER INCOME | | | | | | | | | | | | | | | | | Dividend income | | | - | | | | 21,752 | | | | - | | | | 21,752 | | Interest income | | | 63,646 | | | | 10,468 | | | | - | | | | 74,114 | | Fair value gain on investments in equity securities | | | - | | | | 28,256 | | | | - | | | | 28,256 | | Gain on disposal of investments in equity securities | | | - | | | | 42,376 | | | | - | | | | 42,376 | | Others | | | 10,919 | | | | 136,312 | | | | - | | | | 147,231 | | | | | | | | | | | | | | | | | | | TOTAL OTHER INCOME | | | 74,565 | | | | 239,164 | | | | - | | | | 313,729 | | | | | | | | | | | | | | | | | | | OPERATING EXPENSES | | | | | | | | | | | | | | | | | Sales and marketing | | | (86,275 | ) | | | (1,577,214 | ) | | | (37,202 | ) | | | (1,700,691 | ) | Research and development | | | (39,572 | ) | | | - | | | | - | | | | (39,572 | ) | General and administrative | | | (270,725 | ) | | | (492,464 | ) | | | (600,888 | ) | | | (1,364,077 | ) | Fair value loss on investments in equity securities | | | - | | | | (119,499 | ) | | | - | | | | (119,499 | ) | Provision for credit losses, net | | | - | | | | (121,030 | ) | | | - | | | | (121,030 | ) | | | | | | | | | | | | | | | | | | TOTAL OPERATING EXPENSES | | | (396,572 | ) | | | (2,310,207 | ) | | | (638,090 | ) | | | (3,344,869 | ) | | | | | | | | | | | | | | | | | | LOSS FROM OPERATIONS | | | (315,700 | ) | | | (988,150 | ) | | | (638,090 | ) | | | (1,941,940 | ) | | | | | | | | | | | | | | | | | | FINANCE COSTS | | | (32 | ) | | | (6,266 | ) | | | (252 | ) | | | (6,550 | ) | | | | | | | | | | | | | | | | | | LOSS BEFORE TAX | | | (315,732 | ) | | | (994,416 | ) | | | (638,342 | ) | | | (1,948,490 | ) | | | | | | | | | | | | | | | | | | Tax expense | | | - | | | | - | | | | - | | | | - | | | | | | | | | | | | | | | | | | | NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | | $ | (315,732 | ) | | $ | (994,416 | ) | | $ | (638,342 | ) | | $ | (1,948,490 | ) |
By Country | | Malaysia | | | United States | | | Total | | | | Nine-month period ended September 30, 2026 | | | | | | | | | | | | REVENUE | | $ | 146,915 | | | $ | - | | | $ | 146,915 | | | | | | | | | | | | | | | COST OF REVENUE | | | (130,235 | ) | | | - | | | | (130,235 | ) | | | | | | | | | | | | | | GROSS PROFIT | | | 16,680 | | | | - | | | | 16,680 | | | | | | | | | | | | | | | OTHER INCOME | | | | | | | | | | | | | Interest income | | | 54,903 | | | | - | | | | 54,903 | | Gain from foreign exchange | | | 10,017 | | | | 48 | | | | 10,065 | | Others | | | 22,779 | | | | - | | | | 22,779 | | TOTAL OTHER INCOME | | | 87,699 | | | | 48 | | | | 87,747 | | | | | | | | | | | | | | | OPERATING EXPENSES | | | | | | | | | | | | | Sales and marketing | | | (100,944 | ) | | | (22,818 | ) | | | (123,762 | ) | Research and development | | | (41,736 | ) | | | - | | | | (41,736 | ) | General and administrative | | | (342,908 | ) | | | (600,034 | ) | | | (942,942 | ) | Provision for credit losses, net | | | (76,814 | ) | | | - | | | | (76,814 | ) | Share-based compensation | | | - | | | | (799,998 | ) | | | (799,998 | ) | TOTAL OPERATING EXPENSES | | | (562,402 | ) | | | (1,422,850 | ) | | | (1,985,252 | ) | | | | | | | | | | | | | | LOSS FROM OPERATIONS | | | (458,023 | ) | | | (1,422,802 | ) | | | (1,880,825 | ) | | | | | | | | | | | | | | FINANCE COSTS | | | (1,574 | ) | | | (2,007 | ) | | | (3,581 | ) | | | | | | | | | | | | | | LOSS BEFORE TAX | | | (459,597 | ) | | | (1,424,809 | ) | | | (1,884,406 | ) | | | | | | | | | | | | | | Tax expense | | | - | | | | - | | | | - | | | | | | | | | | | | NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | | $ | (459,597 | ) | | $ | (1,424,809 | ) | | $ | (1,884,406 | ) |
By Country | | Malaysia | | | United States | | | Total | | | | Nine-month period ended September 30, 2025 | | | | | | | | | | | | REVENUE | | $ | 6,941,151 | | | $ | - | | | $ | 6,941,151 | | | | | | | | | | | | | | | COST OF REVENUE | | | (5,851,951 | ) | | | - | | | | (5,851,951 | ) | | | | | | | | | | | | | | GROSS PROFIT | | | 1,089,200 | | | | - | | | | 1,089,200 | | | | | | | | | | | | | | | OTHER INCOME | | | | | | | | | | | | | Dividend income | | | 21,752 | | | | - | | | | 21,752 | | Interest income | | | 74,114 | | | | - | | | | 74,114 | | Fair value gain on investments in equity securities | | | 28,256 | | | | - | | | | 28,256 | | Gain on disposal of investments in equity securities | | | 42,376 | | | | - | | | | 42,376 | | Others | | | 147,231 | | | | | | | | 147,231 | | TOTAL OTHER INCOME | | | 313,729 | | | | - | | | | 313,729 | | | | | | | | | | | | | | | OPERATING EXPENSES | | | | | | | | | | | | | Sales and marketing | | | (1,663,489 | ) | | | (37,202 | ) | | | (1,700,691 | ) | Research and development | | | (39,572 | ) | | | - | | | | (39,572 | ) | General and administrative | | | (763,189 | ) | | | (600,888 | ) | | | (1,364,077 | ) | Fair value loss on investments in equity securities | | | (119,499 | ) | | | - | | | | (119,499 | ) | Provision for credit losses, net | | | (121,030 | ) | | | - | | | | (121,030 | ) | TOTAL OPERATING EXPENSES | | | (2,706,779 | ) | | | (638,090 | ) | | | (3,344,869 | ) | | | | | | | | | | | | | | LOSS FROM OPERATIONS | | | (1,303,850 | ) | | | (638,090 | ) | | | (1,941,940 | ) | | | | | | | | | | | | | | FINANCE COSTS | | | (6,298 | ) | | | (252 | ) | | | (6,550 | ) | | | | | | | | | | | | | | LOSS BEFORE TAX | | | (1,310,148 | ) | | | (638,342 | ) | | | (1,948,490 | ) | | | | | | | | | | | | | | Tax expense | | | - | | | | - | | | | - | | | | | | | | | | | | | | | NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | | $ | (1,310,148 | ) | | $ | (638,342 | ) | | $ | (1,948,490 | ) |
| | Provision for genomic screening services | | | Trading of industrial chemicals | | | Investment holding | | | Total | | | | As of September 30, 2026 | | | | | | | | | | | | | | | Segment assets | | $ | 1,643,808 | | | $ | 4,250,922 | | | $ | 2,865,971 | | | $ | 8,760,701 | | | | | | | | | | | | | | | | | | | Included in the measure of segment assets are: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Addition to non-current assets other than financial instruments and deferred tax assets | | | 163 | | | | 78,323 | | | | - | | | | 78,486 | |
| | Provision for genomic screening services | | | Trading of industrial chemicals | | | Investment holding | | | Total | | | | As of December 31, 2025 | | | | | | | | | | | | | | | Segment assets | | $ | 2,281,947 | | | $ | 4,577,690 | | | $ | 2,393,147 | | | $ | 9,252,784 | | | | | | | | | | | | | | | | | | | Included in the measure of segment assets are: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Addition to non-current assets other than financial instruments and deferred tax assets | | | 1,382 | | | | 35,589 | | | | - | | | | 36,971 | |
The Company had no inter-segment sales for the periods presented.
|